Latest Streaming News

dorsaVi reported a modest 1.9% rise in sales revenue to $330k in Q2 FY25, launched its AI-powered Video AI movement analysis platform, and initiated a blockchain integration partnership to enhance data security.

IMEXHS Limited reported a robust 34% increase in FY24 revenue to $26.5 million, driven by new contracts in Colombia and Peru that boosted its Annual Recurring Revenue to $30 million. Despite a slight EBITDA shortfall due to a bad debt expense, the company highlighted operational improvements and strengthened its regional footprint.

InFocus Group Holdings has marked a pivotal quarter with a major $2.5 million contract in digital gaming and a corporate rebrand signaling its shift to enterprise software and analytics. The imminent Prodigy9 acquisition and capital raise position the company for accelerated growth.

Golden Horse Minerals Ltd posted a CAD 413,000 net cash outflow from operating activities in the December 2024 quarter, while maintaining a robust cash balance of CAD 13.37 million. The company’s cash burn reflects ongoing exploration and evaluation investments.

Titan Minerals has made significant strides in its Ecuadorian copper and gold projects, securing a $20 million capital raise and progressing key drilling milestones under a major joint venture agreement.

Mastermyne Group Limited reported a 14% rise in EBITDA to $4.1 million for FY25 Q2, even as revenue fell 10% due to operational disruptions at Anglo American’s Grosvenor mine. The company secured key contract extensions and maintained a strong cash position, positioning itself for growth amid sector uncertainties.

Prophecy International has inked a three-year global reseller agreement with US SIEM leader Securonix, aiming to generate over $1 million in new annual recurring revenue within the first year.

Osteopore Limited reports a robust 27% year-over-year revenue increase despite operational headwinds, underpinned by new collaborations in stem cell therapies and expanded market access in Brazil and Singapore.

Mesoblast has secured FDA approval for Ryoncil®, the first mesenchymal stromal cell therapy for steroid-refractory acute graft versus host disease in children, while raising A$260 million to accelerate clinical trials and commercial rollout.

Eden Innovations Ltd reports a striking 158% increase in US OptiBlend® sales for Q2 FY25, alongside expanding international traction for its EdenCrete® products and strategic property sales aimed at debt reduction.

Orcoda Limited reports robust SaaS revenue growth in its Transport Technology division for 1H FY25, offsetting challenges in its Infrastructure Services business. The company maintains optimism for future contracts and strategic expansion.

ResMed Inc. has announced a quarterly ordinary dividend of USD 0.053 per share for holders of its ASX-listed Chess Depositary Instruments, with payments scheduled for March 2025.